High-Dose Mitochondria, RET, and ROS

At very high pharmacological exposures, melatonin is not framed here as a simple antioxidant.

The proposed model is that it can push some tumour cells into a mitochondrial redox crisis.

The core sequence

1. High-dose melatonin pushes tumour mitochondria to burn harder

Melatonin is proposed to push some tumour cells away from a purely glycolytic pattern.

More pyruvate is driven into the TCA cycle.

That means more reducing equivalents feed the electron transport chain.

2. Electron traffic backs up and membrane voltage rises

As electron flow rises, the inner mitochondrial membrane becomes more highly charged.

At the same time, the CoQ pool shifts toward its reduced form.

In source-language terms, the CoQH₂ to CoQ ratio rises sharply.

That combination matters because RET does not happen in a neutral setting.

It needs a highly energised membrane and a backed-up electron-carrier pool.

3. Reverse electron transport starts at Complex I

Under those conditions, electrons can move backward from reduced CoQ into Complex I.

That is the RET step.

Instead of normal forward flow toward oxygen, the system partially reverses at Complex I.

4. A short mitochondrial ROS burst follows

When Complex I runs in that reverse-loaded state, electron leak increases.

Superoxide rises sharply.

This is not framed as a slow background increase.

It is a short, high-intensity mitochondrial ROS event.

5. Uncoupling and apoptosis follow

The ROS burst destabilises the proton gradient.

ATP production becomes less efficient.

Stress signalling rises.

If the cell cannot buffer that shift, the result is mitochondrial dysfunction, uncoupling, and apoptotic signalling.

Why researchers think RET is the choke-point

Two lines of evidence matter most.

• Complex I blockade can stop the ROS burst.

• Alternative oxidase can bypass the traffic jam.

Rotenone and related ETC blockers can prevent the effect.

Alternative oxidase, or AOX, drains electrons away from the reduced CoQ pool.

That bypass lowers RET pressure, lowers ROS, and reduces cell death.

When that bypass is removed, melatonin's ROS and killing effect return.

That makes RET the key mechanistic bottleneck in the current model.

Why this mechanism matters

The key idea is not just that ROS increases.

It is that melatonin may create the exact high-voltage, over-reduced mitochondrial state that makes RET possible in vulnerable tumour cells.

That is why this mechanism is more specific than a generic antioxidant or pro-oxidant claim.

The claim is about a particular mitochondrial configuration.

Why healthy cells may be spared

Normal cells are less likely to sit near the same RET threshold.

They usually keep a more balanced membrane potential.

They also keep a less backed-up CoQ pool.

Their antioxidant buffering is usually stronger.

In this model, tumour cells are already running metabolically hot.

Melatonin pushes them over the edge.

The selectivity claim therefore depends on baseline context.

It depends on tumour cells already carrying metabolic strain, high membrane potential, and poorer redox control.

What this page does not prove

This mechanism does not show that indefinite oral human mega-dosing reproduces the same state.

It does not show that daily exposure creates a stronger and stronger RET effect.

It does not show that every tumour type will respond the same way.

Just as important, the effect looks transient.

The literature points to a pulse-like ROS event after exposure.

That matters later when people try to translate this mechanism into oral dosing logic.

Big picture

In this high-dose frame, melatonin is being used to reroute mitochondrial traffic inside cancer cells.

The proposed sequence is:

• more pyruvate into the TCA cycle

• more electron pressure into the ETC

• more reduced CoQ and higher membrane voltage

• RET at Complex I

• a brief mitochondrial ROS burst

• uncoupling, damage signalling, and apoptosis

If the cell is already primed for metabolic instability, that sequence may become the trigger for selective collapse.

Related pages

• Melatonin in Oncology - Study Notes — the hub page that ties together the mitochondria, dosing, immune, phase-separation, and fibrosis sections

• Dosing, Bioavailability, and Human Scaling — how mouse and cell data translate into estimated human exposure, route limits, and bioavailability caveats

• Moderate-Dose Immune Effects and Timing — the human oral adjunct literature, Th1 logic, and timing framework

• Addendum — Dosing, Th1/Th2, and Recalibration — why continuous high-dose oral use may work against the immune goal, and how to reassess it

• DIY Liposomal Melatonin — formulation notes, storage, costing, and practical liposomal-delivery context

Key references

• Benaiges et al. 2023 — tumour suppression and mitochondrial ROS in vivo
  https://pmc.ncbi.nlm.nih.gov/articles/PMC5884151/

• Florido et al. 2022 — RET, Complex I, and melatonin-induced ROS in cancer cells
  https://pmc.ncbi.nlm.nih.gov/articles/PMC9404709/